GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (XSWX:KURN) » Definitions » Forward PE Ratio

Kuros Biosciences (XSWX:KURN) Forward PE Ratio : 0.00 (As of May. 30, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Kuros Biosciences Forward PE Ratio?

Kuros Biosciences's Forward PE Ratio for today is 0.00.

Kuros Biosciences's PE Ratio without NRI for today is 0.00.

Kuros Biosciences's PE Ratio for today is 0.00.


Kuros Biosciences Forward PE Ratio Historical Data

The historical data trend for Kuros Biosciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences Forward PE Ratio Chart

Kuros Biosciences Annual Data
Trend
Forward PE Ratio

Kuros Biosciences Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Kuros Biosciences's Forward PE Ratio

For the Medical Devices subindustry, Kuros Biosciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kuros Biosciences's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's Forward PE Ratio falls into.



Kuros Biosciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Kuros Biosciences  (XSWX:KURN) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Kuros Biosciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kuros Biosciences (XSWX:KURN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.

Kuros Biosciences (XSWX:KURN) Headlines

No Headlines